Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Revenue (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Revenue data on record, last reported at $192.6 million in Q4 2025.

  • For Q4 2025, Revenue rose 78.0% year-over-year to $192.6 million; the TTM value through Dec 2025 reached $616.3 million, up 87.32%, while the annual FY2025 figure was $616.3 million, 87.32% up from the prior year.
  • Revenue reached $192.6 million in Q4 2025 per TGTX's latest filing, up from $161.7 million in the prior quarter.
  • Across five years, Revenue topped out at $192.6 million in Q4 2025 and bottomed at $80000.0 in Q4 2022.
  • Average Revenue over 5 years is $59.4 million, with a median of $30.0 million recorded in 2023.
  • Peak YoY movement for Revenue: tumbled 96.55% in 2022, then soared 176298.94% in 2023.
  • A 5-year view of Revenue shows it stood at $2.3 million in 2021, then crashed by 96.55% to $80000.0 in 2022, then soared by 54862.5% to $44.0 million in 2023, then surged by 146.04% to $108.2 million in 2024, then skyrocketed by 78.0% to $192.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $192.6 million in Q4 2025, $161.7 million in Q3 2025, and $141.1 million in Q2 2025.